Welcome to our dedicated page for Trevi Therapeutics SEC filings (Ticker: TRVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trevi Therapeutics, Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company developing Haduvio, oral nalbuphine ER, for chronic cough indications including IPF-related chronic cough, non-IPF interstitial lung disease, and refractory chronic cough. Its 8-K filings report financial results, clinical development updates, FDA meeting disclosures, and material events related to the Haduvio program.
The company’s SEC record also includes registration and offering materials for common stock financings, underwriting agreements, and proxy disclosures covering director elections, executive compensation, governance matters, and equity-based compensation. These filings describe Trevi’s capital structure, development-stage operating profile, and public-company governance.